Cilostazol ameliorates ischemia/reperfusion-induced tight junction disruption in brain endothelial cells by inhibiting endoplasmic reticulum stress

FASEB J. 2019 Sep;33(9):10152-10164. doi: 10.1096/fj.201900326R. Epub 2019 Jun 11.

Abstract

Endoplasmic reticulum (ER) stress is essential for brain ischemia/reperfusion (I/R) injury. However, whether it contributes to I/R-induced blood-brain barrier (BBB) injury remains unclear. cilostazol exerts protective effects toward I/R-induced BBB injury, with unclear mechanisms. This study explored the potential role of ER stress in I/R-induced endothelial cell damage and determined whether the therapeutic potential of cilostazol, with respect to I/R-induced endothelial cell damage, is related to inhibition of ER stress. We found that exposing brain endothelial cells (bEnd.3) to oxygen-glucose deprivation/reoxygenation (OGD/R) significantly activated ER stress and diminished the barrier function of cell monolayers; treatment with the ER stress inhibitor 4-phenylbutyric acid (4-PBA) or cilostazol prevented OGD/R-induced ER stress and preserved barrier function. Furthermore, OGD/R induced the expression and secretion of matrix metalloproteinase-9 and nuclear translocation of phosphorylated NF-κB. These changes were partially reversed by 4-PBA or cilostazol treatment. In vivo, 4-PBA or cilostazol significantly attenuated I/R-induced ER stress and ameliorated Evans blue leakage and tight junction loss. These results demonstrate that I/R-induced ER stress participates in BBB disruption. Targeting ER stress could be a useful strategy to protect the BBB from ischemic stroke, and cilostazol is a promising therapeutic agent for this process.-Nan, D., Jin, H., Deng, J., Yu, W., Liu, R., Sun, W., Huang, Y. Cilostazol ameliorates ischemia/reperfusion-induced tight junction disruption in brain endothelial cells by inhibiting endoplasmic reticulum stress.

Keywords: Ischemia/reperfusion injury; blood-brain barrier disruption; endothelial cell; paracellular permeability.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood-Brain Barrier / drug effects*
  • Blood-Brain Barrier / physiology
  • Cells, Cultured
  • Cilostazol / pharmacology
  • Cilostazol / therapeutic use*
  • Cyclic AMP / metabolism
  • Drug Evaluation, Preclinical
  • Endoplasmic Reticulum Stress / drug effects
  • Endothelial Cells / drug effects*
  • Endothelial Cells / physiology
  • Glucose / pharmacology
  • Infarction, Middle Cerebral Artery / complications
  • Infarction, Middle Cerebral Artery / drug therapy
  • Infarction, Middle Cerebral Artery / physiopathology
  • Male
  • Matrix Metalloproteinase 9 / physiology
  • Mice
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use*
  • Oxygen / pharmacology
  • Phenylbutyrates / pharmacology
  • Random Allocation
  • Rats
  • Rats, Sprague-Dawley
  • Reperfusion Injury / drug therapy*
  • Reperfusion Injury / etiology
  • Reperfusion Injury / physiopathology
  • Single-Blind Method
  • Tight Junctions / drug effects*

Substances

  • Neuroprotective Agents
  • Phenylbutyrates
  • 4-phenylbutyric acid
  • Cyclic AMP
  • Matrix Metalloproteinase 9
  • Mmp9 protein, mouse
  • Mmp9 protein, rat
  • Glucose
  • Cilostazol
  • Oxygen